title: GPR30 is overexpressed in post-puberal testicular germ cell tumors.
abstract: GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to 17β-estradiol and environmental estrogens. In this study, we have evaluated by immunohistochemical analysis GPR30 expression in post-puberal testicular germ cell tumours (30 seminomas, 5 teratomas, 12 embryonal carcinomas, and 20 intratubular germ cell tumors). The GPR30 protein expression was detected at high level in all intratubular germ cell tumours, seminomas, and embryonal carcinomas, whereas in teratomas the expression was low. The immunohistochemical data were further confirmed by Western blot analysis. GPR30 protein expression has also been analyzed in GC1 and TCam-2 cell lines, respectively derived from immortalized type B murine spermatogonia and human seminoma. Our results indicate that GPR30 could be a potential therapeutic target; the design of a specific GPR30 inhibitors could be a useful molecular target to block neoplastic germ cells with a high proliferative rate for the treatment of TGCTs.
authors.affiliation: Istituto Nazionale dei Tumori "Fondazione G. Pascale" , Università di Napoli “Federico II”, Naples, Italy.
authors.forename: Renato
authors.initials: R
authors.lastname: Franco
authors.forename: Francesca
authors.initials: F
authors.lastname: Boscia
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Gigantino
authors.forename: Laura
authors.initials: L
authors.lastname: Marra
authors.forename: Francesco
authors.initials: F
authors.lastname: Esposito
authors.forename: Diana
authors.initials: D
authors.lastname: Ferrara
authors.forename: Paolo
authors.initials: P
authors.lastname: Pariante
authors.forename: Gerardo
authors.initials: G
authors.lastname: Botti
authors.forename: Michele
authors.initials: M
authors.lastname: Caraglia
authors.forename: Sergio
authors.initials: S
authors.lastname: Minucci
authors.forename: Paolo
authors.initials: P
authors.lastname: Chieffi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D018236:Carcinoma, Embryonal / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015195:Drug Design; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D011960:Receptors, Estrogen / Q000032:analysis / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D043562:Receptors, G-Protein-Coupled / Q000032:analysis / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D018239:Seminoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013724:Teratoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C109584:GPER1 protein, human; D011960:Receptors, Estrogen; D043562:Receptors, G-Protein-Coupled